You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians » Physicians' concerns about the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:physicians:concerns [06.01.2019] – [Read also] sallieqhome:physicians:concerns [06.05.2019] – [Read also] sallieq
Line 1: Line 1:
 ====== Physicians' concerns about the Marshall Protocol ====== ====== Physicians' concerns about the Marshall Protocol ======
 +
 +<relatedarticle> [[home:starting:physician:reluctant#specific_research|Section  to print off - Independant research into Olmesartan with PMIDs for doctor.]] </article>
  
 Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|available evidence]]. Over the years, physicians have voiced various concerns about the Marshall Protocol, concerns ranging from the safety of higher doses of olmesartan (Benicar) to concerns about long-term antibiotic use. The Autoimmunity Research Foundation has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the [[home:physicians:concerns#concerns_about_lack_of_clinical_evidence|available evidence]].
Line 16: Line 18:
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))
-  * more recent material on patient response, see below update+  * 2013 material on patient response, see section below 
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
Line 113: Line 115:
  
  
-{{tag>resources_for_physicians}}+{{tag>resources_for_physicians research}}
  
-[[home:starting:physician:reluctant#specific_research|Section  to print off - Independant research into Olmesartan with PMIDs for doctor.]]+[[home:starting:physician:reluctant#Specific_research|Section  to print off - Independent research into Olmesartan with PMIDs for doctor.]]
 ===== Notes and comments ===== ===== Notes and comments =====
  
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.